Press Releases Archives - Psyence Biomedical

Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing

Psyence Group2026-05-17T16:49:30+02:00May 16, 2026|Investor Information, Press Releases|

Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived psychedelic compounds for clinical research and therapeutic applications, today announced that members of its executive leadership team will travel to the United States in the coming weeks to meet with researchers, institutions, industry leaders, and government stakeholders involved in advancing psychedelic medicine research and policy initiatives.

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

Psyence Group2026-04-24T08:33:33+02:00April 24, 2026|Investor Information, Press Releases|

Psyence BioMed has begun its NPX-5 psilocybin trial, dosing the first patient in a Phase IIb study targeting adjustment disorder in palliative care.

Psyence BioMed Positioned as World’s only Licensed Pharmaceutical Grade Ibogaine Supplier at Source

Psyence Group2026-04-20T14:27:54+02:00April 20, 2026|Investor Information, Press Releases|

Through its investment in and collaboration with PsyLabs, the Company has established a GMP-compliant, pharmaceutical-grade supply chain

Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine

Psyence Group2026-04-17T08:13:23+02:00April 17, 2026|Investor Information, Press Releases|

Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities

Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities

Psyence Group2026-04-08T15:55:33+02:00April 8, 2026|Investor Information, Press Releases|

Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities

Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone

Psyence Group2026-03-11T09:53:37+02:00March 11, 2026|Investor Information, Press Releases|

Psyence BioMed reinforces its vertically integrated pharmaceutical platform through its investment in PsyLabs, securing GMP manufacturing, compound supply, and long term commercial infrastructure.

Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial

Psyence Group2026-03-03T14:39:36+02:00March 3, 2026|Investor Information, Press Releases|

Psyence BioMed Put Option exercised by PsyLabs initiates a $5 million share for share exchange, deepening strategic alignment and reinforcing long term access to pharmaceutical grade psychedelic supply as clinical programs advance.

Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment

Psyence Group2026-02-25T14:34:40+02:00February 21, 2026|Investor Information, Press Releases|

Psyence BioMed Put Option exercised by PsyLabs initiates a $5 million share for share exchange, deepening strategic alignment and reinforcing long term access to pharmaceutical grade psychedelic supply as clinical programs advance.

Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

Psyence Group2026-02-25T15:10:37+02:00February 16, 2026|Investor Information, Press Releases|

Psyence BioMed Annual and Special Meeting results confirm shareholder approval of directors, auditors and potential share consolidation authority of up to 250 to 1.

Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway

Psyence Group2026-02-16T08:46:55+02:00February 15, 2026|Investor Information, Press Releases|

The Put Option Agreement positions Psyence BioMed for potential significant future equity participation in one of the world's most advanced psychedelic pharmaceutical grade manufacturers, thereby securing predictable and reliable supply of pharmaceutical grade psychedelics, as the pathway to commercialization unfolds.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.